Vasodilating versus First-Generation β-Blockers for Cardiovascular Protection

References

• . Centers for Disease Control and Prevention. Vital signs: prevalence, treatment, and control of hypertension—United States, 1999–2002 and 2005–2008. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6004a4.htm?s_cid=mm6004a4_w. Updated February 4, 2011. Accessed April 10, 2011
   Google Scholar
• . Davy K P, Hall JE. Obesity and hypertension: two epidemics or one? Am J Physiol Regul Integr Comp Physiol. 2004;286:R803–R813
   PubMed Web of Science ®Google Scholar
• . Ram C V. Beta-blockers in hypertension. Am J Cardiol. 2010;106(12):1819–1825
   PubMed Web of Science ®Google Scholar
• . Lavie CJ, Messerli FH, Milani RV. Beta-blockers as first-line antihypertensive therapy: the crumbling continues. Am Coll Cardiol. 2009;54(13):1162–1164
   PubMed Web of Science ®Google Scholar
• . Mansoor AH, Kaul U. Beta-blockers in cardiovascular medicine. JAPI. 2009;57:7–12
   Google Scholar
• . Gorre F, Vandekerckhove H. Beta-blockers: focus on mechanism of action. Acta Cardiol. 2010;65(5):565–570
   PubMed Web of Science ®Google Scholar
• . Che Q, Schreiber MJ, Rafey MA. Beta-blockers for hypertension: are they going out of style? CCJM. 2009;76(6):533–542
   Google Scholar
• . Mairesse S, Blacher J, Safar ME. Focus on beta-blockers for vascular specialists in 2012 [in French]. J Mal Vasc. 2011;36(6):339–347
   PubMedGoogle Scholar
• . Reiffel JA, Hhn E, Hartz V, Reiter MJ. Sotalol for ventricular tachyarrhythmias: beta-blocking and class III contributions, and relative efficacy versus class I drugs after prior drug failure. ESVEM Investigators. Electrophysiologic Study Versus Electrocardiographic Monitoring. Am J Cardiol. 1997;79(8):1048–1053
   PubMed Web of Science ®Google Scholar
• . Devereaus PJ, Yang H, Yusuf S, . Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE Trial): a randomised controlled trial. Lancet. 2008;371(9627):1839–1847
   PubMed Web of Science ®Google Scholar
• . Deedwania P. Hypertension, dyslipidemia, and insulin resistance in patients with diabetes mellitus or the cardiometabolic syndrome: benefits of vasodilating B-blockers. J Clin Hypertension. 2011;13(1):52–59
   PubMed Web of Science ®Google Scholar
• . Jacob S, Henriksen EJ. Metabolic properties of vasodilating B-blockers: management considerations for hypertensive diabetic patients and patients with the metabolic syndrome. J Clin Hypertension. 2004;6(12):690–698
   Google Scholar
• . Bakris G. An in-depth analysis of vasodilation in the management of hypertension: focus on adrenergic blockade. J Cardiovasc Pharmacol. 2009;53(5):379–387
   PubMed Web of Science ®Google Scholar
• . Agabiti—Rosei E, Porteri E, Rizzoni D. Arterial stiffness, hypertension, and rational use of nebivolol. Vasc Health Risk Manag. 2009;5(1):353–360
   PubMedGoogle Scholar
• . Preston RA, Materson BJ, Reda DJ, . Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. JAMA. 1998;280(13):1168–1172
   PubMed Web of Science ®Google Scholar
• . Furberg CD. Renin test-guided drug treatment of hypertension: the need for clinical trials. AJH. 2011;24(11):1158–1163
   Google Scholar
• . Blumenfeld JD, Laragh JH. Renin system analysis: a rational method for the diagnosis and treatment of the individual patient with hypertension. AJH. 1998;11(7):894–896
   Google Scholar
• . Weber MA, Bakris GL, Tarka EA, Iyengar M, Fleck R, Sica DA. Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension. J Clin Hypertens. 2006;8(12):840–849
   PubMedGoogle Scholar
• . Packer M, Lukas MA, Tenero DM, Baidoo CA, Greenberg BH; 369 Study Group. Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction. Am J Cardiol. 2006;98:39L–45L
   PubMed Web of Science ®Google Scholar
• . Henderson LS, Tenero DM, Baidoo CA, . Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension. Am J Cardiol. 2006;98(7A):17L–26L
   PubMed Web of Science ®Google Scholar
• . Dawson A, Rana BS, Pringle SD, . How much echo left ventricular hypertrophy would be missed in diabetics by applying the Losartan Intervention For Endpoint Reduction electrocardiogram criteria to select patients for angiotensin receptor blockade? J Hypertens. 2004;22(7):1403–1408
   PubMed Web of Science ®Google Scholar
• . Leese PJ, Viera AJ, Hinderliter AL, Steams SC. Cost-effectiveness of electrocardiography vs. electrocardiography plus limited echocardiography to diagnose LV H in young, newly identified, hypertensives. Am J Hypertens. 2010;23(6):592–598
   PubMed Web of Science ®Google Scholar
• . Ventura HO. Benefits of Inpatient Initiation of beta-blockers. Am Heart J. 2004;148(6):944–950
   PubMed Web of Science ®Google Scholar
• . Pedersena ME, Cockroftb JR. What is the role, if any, for beta-blockers as initial therapy for uncomplicated hypertension? Curr Opin Cardiol. 2009;24(4):325–332
   PubMed Web of Science ®Google Scholar
• . Gupta S, Harold M. Nebivolol: a highly selective β1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide. Cardiovasc Ther. 2008;26(3):189–202
   PubMed Web of Science ®Google Scholar
• . Giles T. The role of vasodilating blockers in patients with complicated hypertension: focus on nebivolol. Am J Med. 2010;123(7 suppl 1): S16–S20
   Web of Science ®Google Scholar
• . Munzel T, Gori T. Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol. 2009;54(16):1491–1499
   PubMed Web of Science ®Google Scholar
• . Stafylas PC, Sarafidis PA. Carvedilol in hypertension treatment. Vasc Health Risk Manag. 2008;4(1):23–30
   PubMedGoogle Scholar
• . Sarafidis PA, Bakris GL. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. Q J Med. 2006;99(7):431–436
   Google Scholar
• . Mollnau H, Schulz E, Daiber A, . Nebivolol prevents vascular NOS III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells. Arterioscler Thromb Vasc Biol. 2003;23(4):615–621
   PubMed Web of Science ®Google Scholar
• . Bakris GL, Fonseca F, Katholi RE, ; GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension. JAMA. 2004;292(18):2227–2236
   PubMed Web of Science ®Google Scholar
• . Bakris GL, Hart P, Ritz E. Beta blockers in the management of chronic kidney disease. Kidney Int. 2006;70(11):1905–1913
   PubMed Web of Science ®Google Scholar
• . Bangalore S, Messerli FH, Kostis JB, . Cardiovascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol. 2007;50(7):563–572
   PubMed Web of Science ®Google Scholar
• . Dessy C, Saliez J, Ghisdal P, . Endothelial B3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation B-blocker nebivolol. Circulation. 2005;112(8):1198–1205
   PubMed Web of Science ®Google Scholar
• . Bakris GL, Basile JN, Giles TD, Taylor AA. The role of nitric oxide in improving endothelial function and cardiovascular health: focus on nebivolol. Am J Med. 2010;123(7 suppl 1):S2–S8
   Web of Science ®Google Scholar
• . Cannon RO. Role of nitric oxide in cardiovascular disease: focus on the endothelium. Clin Chem. 1998;44(8):1809–1819
   PubMed Web of Science ®Google Scholar
• . McEniery CM, Hall IR, Qasem A, Wilkinson IB, Cockcroft JR. Normal vascular aging: differential effects on wave refection and aortic pulse wave velocity: The Anglo-Cardiff Callobarative Trial (ACCT). J Am Coll Cardiol. 2005;46(9):1753–1760
   PubMed Web of Science ®Google Scholar
• . Nichols W W, Edwards DG. Arterial elastance and wave refection augmentation of systolic blood pressure: deleterious effects and implications for therapy. J Cardiovasc Pharmacol Ther. 2001;6(1):5–21
   PubMedGoogle Scholar
• . Adji1 A, O'Rourke M, Namasivayam M. Arterial stiffness, its assessment, prognostic value, and implications for treatment. Am J Hypertens. 2011;24(1):5–17
   PubMed Web of Science ®Google Scholar
• . Saunders E, Weir MR, Bong BW, . A comparison of the efficacy and safety of a B-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med. 1990;150(8):1707–1713
   PubMedGoogle Scholar
• . Brehm BR, Bertsch D, von Fallois J, Wolf SC. Beta-blockers of the third generation inhibit endothelin-1 liberation, mRNA production and proliferation of human coronary smooth muscle and endothelial cells. J Cardiovasc Pharmacol. 2000;36( 5 suppl):S401–S403
   Web of Science ®Google Scholar
• . Brehm BR, Wolf SC, Bertsch D, . Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc Res. 2011;49(2):430–439
   Google Scholar
• . Garbin U, Fratta Pasini A, Stranieri C, . Effects of nebivolol on endothelial gene expression during oxidative stress in human umbilical vein endothelial cells. Mediators Inflamm. 2008;2008:367590
   PubMed Web of Science ®Google Scholar
• . Wolf SC, Sauter G, Jobst J, Kempf VA, Risler T, Brehm BR. Major differences in gene expression in human coronary smooth muscle cells after nebivolol or metoprolol treatment. Int J Cardiol. 2008;125(1):4–10
   PubMed Web of Science ®Google Scholar
• . de Nigris F, Mancini F P, Balestrieri ML, . Therapeutic dose of nebivolol, a nitric oxide-releasing beta-blocker, reduces atherosclerosis in cholesterol-fed rabbits. Nitric Oxide. 2008;19(1):57–63
   PubMed Web of Science ®Google Scholar
• . Van Bortel LM, van Baak MA. Exercise tolerance with nebivolol and atenolol. Cardiovasc Drugs Ther. 1992;6(3):239–247
   PubMed Web of Science ®Google Scholar
• . Galderisi M, D'Errico A. Beta-blockers and coronary flow reserve: the importance of a vasodilatory action. Drugs. 2008;68(5):579–590
   PubMed Web of Science ®Google Scholar
• . Taylor AA, Bakris GL. The role of vasodilating β-blockers in patients with hypertension and the cardiometabolic syndrome. Am J Med. 2010;123:S21–S26
   PubMed Web of Science ®Google Scholar
• . Flather MD, Shibata MC, Coats AJ, . Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215–225
   PubMed Web of Science ®Google Scholar
• . Veverka A, Salinas JL. Nebivolol in the treatment of chronic heart failure. Vasc Health Risk Manag. 2007;3(5):647–654
   PubMedGoogle Scholar
• . Patrianakos A P, Parthenakis FI, Mavrakis HE, . Comparative efficacy of nebivolol versus carvedilol on left ventricular function and exercise capacity in patients with nonischemic dilated cardiomyopathy. A 12-month study. Am Heart J. 2005;150(985):e9–e18
   Google Scholar
• . Lombardo RM, Reina C, Abrignani MG, . Effects of nebivolol versus carvedilol on left ventricular function in patients with chronic heart failure and reduced left ventricular systolic function. Am J Cardiovasc Drugs. 2006;6(4):259–263
   PubMedGoogle Scholar
• . Ventura H, Pina IL, Lavie CJ. Hypertension and antihypertensive therapy in the Hispanics or Mexican Americans living in the United States. Postgrad Med. 2011;123(6):46–57
   PubMed Web of Science ®Google Scholar